menu
    • menu

    Find Phenobarbital manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 2
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    29

    API Suppliers

    7

    USDMF

    6

    CEP/COS

    10

    JDMF

    3

    EU WC

    0

    KDMF

    10

    NDC API

    0

    VMF

    8

    Listed Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    3

    EDQM

    0

    USP

    0

    JP

    1

    Others

    FINISHED DOSAGE FORMULATIONS

    89

    FDF Dossiers

    0

    FDA Orange Book

    60

    Europe

    10

    Canada

    2

    Australia

    7

    South Africa

    10

    Listed Dossiers

    2PROSPECTS

    2DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    154RELATED EXCIPIENT COMPANIES

    230EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    15,458,826

    Annual Reports

    NA

    Regulatory FDF Prices

    MARKET PLACE

    23

    API

    8

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    12

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Phenobarbitone, Luminal, Phenobarbitol, 50-06-6, Phenylethylbarbiturate, Phenobarbituric acid
    Molecular Formula
    C12H12N2O3
    Molecular Weight
    232.23  g/mol
    InChI Key
    DDBREPKUVSBGFI-UHFFFAOYSA-N
    FDA UNII
    YQE403BP4D
    Phenobarbital
    A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
    1 2D Structure

    Phenobarbital

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
    2.1.2 InChI
    InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
    2.1.3 InChI Key
    DDBREPKUVSBGFI-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
    2.2 Other Identifiers
    2.2.1 UNII
    YQE403BP4D
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Acid, Phenylethylbarbituric

    2. Gardenal

    3. Hysteps

    4. Luminal

    5. Monosodium Salt Phenobarbital

    6. Phenemal

    7. Phenobarbital Sodium

    8. Phenobarbital, Monosodium Salt

    9. Phenobarbitone

    10. Phenylbarbital

    11. Phenylethylbarbituric Acid

    12. Sodium, Phenobarbital

    2.3.2 Depositor-Supplied Synonyms

    1. Phenobarbitone

    2. Luminal

    3. Phenobarbitol

    4. 50-06-6

    5. Phenylethylbarbiturate

    6. Phenobarbituric Acid

    7. Phenylethylmalonylurea

    8. Fenobarbital

    9. Gardenal

    10. Phenemal

    11. Adonal

    12. Phenylethylbarbituric Acid

    13. Nunol

    14. Gardepanyl

    15. Neurobarb

    16. Phenaemal

    17. Dormiral

    18. Hysteps

    19. Aphenylbarbit

    20. Aphenyletten

    21. Dezibarbitur

    22. Lepinaletten

    23. Lumofridetten

    24. Aephenal

    25. Agrypnal

    26. Amylofene

    27. Barbenyl

    28. Barbiphenyl

    29. Barbipil

    30. Barbivis

    31. Barbonal

    32. Barbophen

    33. Bialminal

    34. Cabronal

    35. Calmetten

    36. Calminal

    37. Cardenal

    38. Codibarbita

    39. Coronaletta

    40. Cratecil

    41. Doscalun

    42. Ensobarb

    43. Ensodorm

    44. Episedal

    45. Epsylone

    46. Eskabarb

    47. Fenbital

    48. Fenylettae

    49. Glysoletten

    50. Haplopan

    51. Hennoletten

    52. Hypnaletten

    53. Hypnette

    54. Hypnogen

    55. Hypnolone

    56. Hypnoltol

    57. Liquital

    58. Lixophen

    59. Lubergal

    60. Lubrokal

    61. Lumesettes

    62. Luphenil

    63. Nirvonal

    64. Parkotal

    65. Pharmetten

    66. Phenemalum

    67. Phenobal

    68. Phenobarbyl

    69. Phenoluric

    70. Phenolurio

    71. Phenomet

    72. Phenonyl

    73. Phenoturic

    74. Phenyletten

    75. Phenyral

    76. Polcominal

    77. Promptonal

    78. Sedizorin

    79. Sedonettes

    80. Sedophen

    81. Solfoton

    82. Sombutol

    83. Somnolens

    84. Somnoletten

    85. Somnosan

    86. Spasepilin

    87. Starifen

    88. Starilettae

    89. Teolaxin

    90. Versomnal

    91. Barbita

    92. Bardorm

    93. Bartol

    94. Chinoin

    95. Duneryl

    96. Epanal

    97. Epidorm

    98. Epilol

    99. Etilfen

    100. Euneryl

    101. Fenemal

    102. Fenosed

    103. Haplos

    104. Henotal

    105. Leonal

    106. Lepinal

    107. Linasen

    108. Lumesyn

    109. Luramin

    110. Molinal

    111. Noptil

    112. Sedabar

    113. Sedicat

    114. Sedlyn

    115. Sedofen

    116. Sedonal

    117. Sevenal

    118. Somonal

    119. Lumen

    120. Seda-tablinen

    121. 5-ethyl-5-phenylbarbituric Acid

    122. Blu-phen

    123. Nova-pheno

    124. Solu-barb

    125. Hypno-tablinetten

    126. Stental Extentabs

    127. Phen-bar

    128. Phob

    129. Phenobarb

    130. Talpheno

    131. Triabarb

    132. Triphenatol

    133. 5-phenyl-5-ethylbarbituric Acid

    134. Phenobarbitalum

    135. Tridezibarbitur

    136. Zadoletten

    137. Barbinal

    138. Barbiphen

    139. Damoral

    140. Dormina

    141. Lefebar

    142. Lephebar

    143. Stental

    144. Teoloxin

    145. Theoloxin

    146. Zadonal

    147. 5-ethyl-5-phenylpyrimidine-2,4,6(1h,3h,5h)-trione

    148. Sk-phenobarbital

    149. Thenobarbital

    150. 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-phenyl-

    151. 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione

    152. Dormital

    153. Tedral

    154. Phenylethylbarbitursaeure

    155. Phenylaethylbarbitursaeure

    156. 5-ethyl-5-phenyl-2,4,6(1h,3h,5h)-pyrimidinetrione

    157. Barbituric Acid, 5-ethyl-5-phenyl-

    158. 5-ethyl-5-phenyl-pyrimidine-2,4,6-trione

    159. Barbilehae (barbilettae)

    160. Component Of Tedral

    161. Sedonal (sedative)

    162. Component Of Slowten

    163. Chebi:8069

    164. Component Of Antrocol

    165. Component Of Hecadrol

    166. Component Of Bronkotabs

    167. 5-ethyl-5-phenyl-2,4,6-(1h,3h,5h)pyrimidinetrione

    168. Phenobarbital Civ

    169. Component Of Primatene P

    170. Nsc-9848

    171. Chembl40

    172. Phenobarbital (in Methanol Solution)

    173. Nsc-128143

    174. Component Of Valpin 50-pb

    175. Yqe403bp4d

    176. Austrominal

    177. Phenobarbitonum

    178. Ncgc00159493-02

    179. Fenobarbitale

    180. Fenobarbitale [dcit]

    181. Elixir Of Phenobarbital

    182. Phenobarbitalum [inn]

    183. Dsstox_cid_1122

    184. Chardonna-2

    185. Dsstox_rid_75953

    186. Dsstox_gsid_21122

    187. Phenylethyl Barbituric Acid

    188. Fenobarbital [inn-spanish]

    189. Phenyl-ethyl-barbituric Acid

    190. Phenobarbitalum [inn-latin]

    191. Wln: T6vmvmv Fhj F2 Fr

    192. Barbinol

    193. Fenemal Recip

    194. Cas-50-06-6

    195. Levsin Pb Drops And Tablets

    196. Ccris 502

    197. Luminal (tn)

    198. Phenobarbital (pb)

    199. Acido 5-fenil-5-etilbarbiturico

    200. Hsdb 3157

    201. Acido 5-fenil-5-etilbarbiturico [italian]

    202. 5-ethyl-5-phenyl-2,6(1h,3h,5h)-pyrimidinetrione

    203. Einecs 200-007-0

    204. Unii-yqe403bp4d

    205. 2,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-phenyl-

    206. Nsc 128143

    207. Phenobar

    208. Ai3-02726

    209. Phenobarbital [usp:inn:ban:jan]

    210. Tedral (salt/mix)

    211. Primidone Impurity B

    212. Tedrigen

    213. Theophed

    214. Kinesed (salt/mix)

    215. Antrocol (salt/mix)

    216. Donnatal (salt/mix)

    217. Donnazyme (salt/mix)

    218. Quadrinal (salt/mix)

    219. Mephobarbital M (nor)

    220. Barbidonna (salt/mix)

    221. Bronkotabs (salt/mix)

    222. Tedral Suspension

    223. Chardonna-2 (salt/mix)

    224. Phenobarbital [mi]

    225. Epitope Id:116048

    226. Phenobarbital [inn]

    227. Phenobarbital [jan]

    228. Phenobarbital [hsdb]

    229. Phenobarbital [iarc]

    230. Bidd:pxr0061

    231. Oprea1_384816

    232. Schembl16583

    233. 5-ethyl-5-phenyl-hexahydropyrimidine-2,4,6-trione

    234. Methylphenobarbital, M(nor-)

    235. Mls001240232

    236. Divk1c_000987

    237. Phenobarbital [mart.]

    238. Phenobarbitalum [hpus]

    239. Phenobarbital [who-dd]

    240. Phenobarbital [who-ip]

    241. Gtpl2804

    242. Dtxsid5021122

    243. Schembl11114624

    244. Hms503e15

    245. Kbio1_000987

    246. Nsc9848

    247. Phenobarbital (jp17/usp/inn)

    248. Ninds_000987

    249. Hms2272g06

    250. Phenobarbital [ep Impurity]

    251. Phenobarbital Civ [usp-rs]

    252. Phenobarbital [ep Monograph]

    253. Tox21_111713

    254. Tox21_200510

    255. Bdbm50021437

    256. Nsc128143

    257. Phenobarbital [usp Monograph]

    258. Stl367898

    259. Zinc95588079

    260. Component Of Primatene P (salt/mix)

    261. Phenobarbital 0.1 Mg/ml In Methanol

    262. Phenobarbital 1.0 Mg/ml In Methanol

    263. Akos000605404

    264. Akos015964976

    265. Barbituric Acid, 5-ethyl-5-phenyl-,

    266. Phenobarbitalum [who-ip Latin]

    267. Ab02704

    268. Db01174

    269. Component Of Valpin 50-pb (salt/mix)

    270. Idi1_000987

    271. Nsc-128143-

    272. Levsin Pb Drops And Tablets (salt/mix)

    273. Ncgc00159493-03

    274. Ncgc00159493-04

    275. Ncgc00258064-01

    276. Smr000058986

    277. Primidone Impurity B [ep Impurity]

    278. Db-051722

    279. C07434

    280. D00506

    281. Phenobarbital Solution, 1.0 Mg/ml In Methanol

    282. A827956

    283. Q407241

    284. Sr-01000313151

    285. Methylphenobarbital Impurity A [ep Impurity]

    286. Sr-01000313151-1

    287. Phenobarbital, United States Pharmacopeia (usp) Reference Standard

    288. Phenobarbital Solution, 1 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material

    289. 11097-06-6

    290. Uqa

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 232.23 g/mol
    Molecular Formula C12H12N2O3
    XLogP31.5
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count2
    Exact Mass232.08479225 g/mol
    Monoisotopic Mass232.08479225 g/mol
    Topological Polar Surface Area75.3 Ų
    Heavy Atom Count17
    Formal Charge0
    Complexity339
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Therapeutic Uses

    Anticonvulsants; Carcinogens; Central Nervous System Depressants; Excitatory Amino Acid Antagonists; GABA Modulators; Sedatives, Barbiturate

    National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)

    Phenobarbital is indicated for use as a sedative or as and anticonvulsant for the treatment of generalized and partial seizures.

    Novak, K.M. (ed.). Drug Facts and Comparisons2008 Edition. Wolters Kluwer Health. St. Louis, Missouri 2008., p. 1443

    /Phenobarbital is indicated/ as a hypnotic, for the short term management of of insomnia.

    Novak, K.M. (ed.). Drug Facts and Comparisons2008 Edition. Wolters Kluwer Health. St. Louis, Missouri 2008., p. 1443

    /Phenobarbital is indicated/ as a sedative, for the relief of anxiety, tension,and apprehension.

    Novak, K.M. (ed.). Drug Facts and Comparisons2008 Edition. Wolters Kluwer Health. St. Louis, Missouri 2008., p. 1443

    For more Therapeutic Uses (Complete) data for Phenobarbital (7 total), please visit the HSDB record page.

    4.2 Drug Warning

    Barbiturates have been shown to cause an incr incidence of fetal abnormalities. Risk-benefit must be carefully considered when the medication is required in life-threatening situations or in serious diseases for which other medications cannot be used or are ineffective. /Barbiturates/

    USP Convention. USPDI - Drug Information for the Health Care Professional. 17th ed. Volume I. Rockville, MD: Convention, Inc., 1997. (Plus Updates)., p. 502

    Use of barbiturates throughout the last trimester of pregnancy may cause physical dependence with resulting withdrawal symptoms in the neonate. In infants suffering from long-term exposure in utero, the acute withdrawal syndrome of seizures and hyperirritability has been reported to occur from birth to a delayed onset of up to 14 days. /Barbiturates/

    USP Convention. USPDI - Drug Information for the Health Care Professional. 17th ed. Volume I. Rockville, MD: Convention, Inc., 1997. (Plus Updates)., p. 502

    Use of barbiturates during labor may cause respiratory depression in the neonate, esp the premature neonate, because of immature hepatic function. /Barbiturates/

    USP Convention. USPDI - Drug Information for the Health Care Professional. 17th ed. Volume I. Rockville, MD: Convention, Inc., 1997. (Plus Updates)., p. 503

    The risk of barbiturate-induced hypothermia may be increased in elderly patients, especially with high doses or in acute overdoses of barbiturates. In addition, elderly patients are more likely to have age-related hepatic or renal function impairment, which may require a reduction of dosage in patients receiving a barbiturate. /Barbiturates/

    USP Convention. USPDI - Drug Information for the Health Care Professional. 17th ed. Volume I. Rockville, MD: Convention, Inc., 1997. (Plus Updates)., p. 503

    For more Drug Warnings (Complete) data for Phenobarbital (28 total), please visit the HSDB record page.

    4.3 Minimum/Potential Fatal Human Dose

    The toxic dose of barbiturates varies considerably but, in general, a severe reaction is likely to occur when the amount ingested is more than 10 times the usual oral hypnotic dose. Potentially lethal blood concentrations are those in excess of 80 ug/mL for phenobarbital, 50 ug/mL for amobarbital or butabarbital, and approximately 30 ug/mL for secobarbital or pentobarbital; however, some patients have survived much higher blood concentrations. /Barbiturates General Statement/

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2578

    4.4 Drug Indication

    For the treatment of all types of seizures except absence seizures.

    Treatment of epilepsy

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Phenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal).

    5.2 MeSH Pharmacological Classification

    GABA Modulators

    Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)

    Cytochrome P-450 CYP2B6 Inducers

    Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP2B6. (See all compounds classified as Cytochrome P-450 CYP2B6 Inducers.)

    Cytochrome P-450 CYP3A Inducers

    Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inducers.)

    Anticonvulsants

    Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)

    Excitatory Amino Acid Antagonists

    Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)

    Hypnotics and Sedatives

    Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)

    5.3 ATC Code

    N03AA02

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    N - Nervous system

    N03 - Antiepileptics

    N03A - Antiepileptics

    N03AA - Barbiturates and derivatives

    N03AA02 - Phenobarbital

    5.4 Absorption, Distribution and Excretion

    Absorption

    Absorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach.

    About 70-90% of an oral dose of phenobarbital is absorbed slowly from the GI tract. Following rectal administration of phenobarbital sodium, the drug is readily absorbed from the colon. Following oral administration of phenobarbital, peak blood concentrations are reached in 8-12 hours and peak brain concentrations in 10-15 hours. ... When phenobarbital sodium is administered IV, the onset of action usually occurs within 5 minutes and maximum effects are achieved within 30 minutes. IM or subcutaneous administration of phenobarbital sodium results in a slightly slower onset of action. The duration of action of parenterally administered phenobarbital sodium is usually 4-6 hours.

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2269

    Barbiturates are absorbed in varying degrees following oral, rectal, or im administration. The sodium salts are more rapidly absorbed by all routes of administration than are the acids. The rate of oral absorption is increased when the sodium salt is ingested as a dilute solution or taken on an empty stomach. Alcohol also enhances the rate of absorption, possibly by increasing blood flow through the gastric mucosa. /Barbiturates General Statement/

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2579

    Following oral or rectal administration, the onset of action varies from 10-30 minutes for amobarbital, aprobarbital, butabarbital, pentobarbital, and secobarbital and from 20-60 minutes for metharbital, mephobarbital, and phenobarbital. IM administration results in a slightly faster onset of action. Following iv administration of the sodium salts of amobarbital, pentobarbital, phenobarbital, or secobarbital, the onset of action ranges from almost immediately for methohexital, pentobarbital, and thiopental to 5 minutes for phenobarbital. Maximum effects of thiopental or pentobarbital are achieved within about 1 minute while as much as 30 minutes may be required with administration of phenobarbital. /Barbiturates General Statement/

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2579

    The duration of sedative effects of all the barbiturates is usually 3-6 hours following iv administration and 6-8 hours when the drugs are administered by other routes. There appears to be very little difference in duration of hypnotic action among barbiturates used orally as hypnotics. Therefore, most authorities now believe that barbiturates should be classified according to their intended pharmacologic action (ie, sedative-hypnotic barbiturates and anesthetic barbiturates [methohexital, thiamylal (no longer commercially available in the US), thiopental]), rather than as long-acting (mephobarbital, metharbital, and phenobarbital), intermediate-acting (amobarbital and butabarbital), short-acting (aprobarbital, pentobarbital, and secobarbital), and ultrashort-acting (methohexital, thiopental). /Barbiturates General Statement/

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2579

    For more Absorption, Distribution and Excretion (Complete) data for Phenobarbital (15 total), please visit the HSDB record page.

    5.5 Metabolism/Metabolites

    Hepatic (mostly via CYP2C19).

    Phenobarbital is hydroxylated by the liver to form p-hydroxyphenobarbital, an inactive metabolite. Phenobarbital is a potent inducer of the enzymes involved in the metabolism of other drugs, but there is no conclusive evidence that phenobarbital accelerates its own metabolism.

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2584

    The inactive metabolites of the barbiturates are excreted as conjugates of glucuronic acid.

    Medical Economics Co; Physicians Desk Reference: Generics 2nd ed p.2458 (1996)

    Biotransformation occurs primarily by the hepatic microsomal enzyme system. /Barbiturates/

    USP Convention. USPDI - Drug Information for the Health Care Professional. 17th ed. Volume I. Rockville, MD: Convention, Inc., 1997. (Plus Updates)., p. 502

    Metabolites of phenobarbital sodium produced in rats and guinea pigs are 5-(3,4-dihydroxy-1,5-cyclohexadien-1-yl)-5-ethylbarbituric acid; 5-(1-hydroxyethyl)-5-phenylbarbituric acid; 5-(3,4-dihydroxyphenyl)-5-ethylbarbituric acid; and 5-(4-hydroxyphenyl)-5-ethylbarbituric acid ...

    IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V13 166 (1977)

    For more Metabolism/Metabolites (Complete) data for Phenobarbital (6 total), please visit the HSDB record page.

    Phenobarbital has known human metabolites that include p-Hydroxyphenobarbital.

    Phenobarbital is a known human metabolite of (s)-mephobarbital.

    S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

    5.6 Biological Half-Life

    53 to 118 hours (mean 79 hours)

    The plasma half-life for phenobarbital in adults ranges between 53 and 118 hours with an mean of 79 hours.

    Medical Economics Co; Physicians Desk Reference: Generics 2nd ed p.2458 (1996)

    The plasma half-life for phenobarbital in children and newborns (less than 48 hours old) ranges between 60 to 180 hours with a mean of 110 hours.

    Medical Economics Co; Physicians Desk Reference: Generics 2nd ed p.2458 (1996)

    5.7 Mechanism of Action

    Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.

    /Phenobarbital/ produces anticonvulsant effects in subhypnotic doses. The drug lowers serum bilirubin concentrations in neonates and patients with congenital nonhemolytic unconjugated hyperbilirubinemia and patients with chronic intrahepatic cholestasis, presumably by induction of glucuronyl transferase, the enzyme which conjugates bilirubin.

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2584

    The exact mechanism(s) by which barbiturates exert their effect on the CNS, has not been fully elucidated. However, it is believed that such effects are related, at least partially, to the drugs' ability to enhance the activity of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the CNS, by altering inhibitory synaptic transmissions that are mediated by GABAA receptors. /Barbiturates General Statement/

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2579

    Although the drugs act throughout the CNS, a site of particular sensitivity is the polysynaptic midbrain reticular formation which is concerned with the arousal mechanism. Barbiturates induce an imbalance in central inhibitory and facilitatory mechanisms influencing the cerebral cortex and the reticular formation. The significance of the effect of barbiturates on neurotransmitters is unclear. It appears that the drugs decrease the excitability of both presynaptic and postsynaptic membranes. It has not been determined which of the various actions of barbiturates at cellular and synaptic levels are responsible for their sedative and hypnotic effects. /Barbiturates General Statement/

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2579

    Relatively low doses of the barbiturates depress the sensory cortex, decrease motor activity, and produce sedation and drowsiness. In some patients, however, drowsiness may be preceded by a period of transient elation, confusion, euphoria, or excitement, especially after subhypnotic doses of aprobarbital, pentobarbital, or secobarbital. /Barbiturates General Statement/

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009), p. 2579

    For more Mechanism of Action (Complete) data for Phenobarbital (12 total), please visit the HSDB record page.

    API SUPPLIERS

    read-more
    read-more

    01

    Chemische Fabrik Berg

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2022-432 - Rev 00

    Issue Date : 2023-11-09

    Type : Chemical

    Substance Number : 201

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65319-1450

    Start Marketing Date : 2019-01-14

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT arrow-down
    Moehs Chemische Fabrik Berg

    02

    Moehs Iberica

    Spain

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Japan
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
    Moehs Iberica

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    HRV Pharma

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    HRV Global Life Sciences

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Shandong Xinhua Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Shandong Xinhua Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 27827

    Submission : 2013-12-01

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2017-269 - Rev 01

    Issue Date : 2023-11-03

    Type : Chemical

    Substance Number : 201

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 58624-0520

    Start Marketing Date : 1997-01-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT arrow-down
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Nantong Jinghua Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Nantong Jinghua Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 31321

    Submission : 2017-02-09

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2005-118 - Rev 02

    Issue Date : 2016-10-04

    Type : Chemical

    Substance Number : 201

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 59348-0011

    Start Marketing Date : 2015-11-02

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT arrow-down
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Alkaloida Chemical Company Zrt

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Alkaloida Chemical Company Zrt

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 4642

    Submission : 1982-09-01

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2009-132 - Rev 03

    Issue Date : 2021-12-08

    Type : Chemical

    Substance Number : 201

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 50095-001

    Start Marketing Date : 1982-11-05

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (25kg/25kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT arrow-down
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Country

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 1003

    Submission : 1966-10-19

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Country

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 4714

    Submission : 1982-11-10

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    F. Hoffmann-La Roche

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    F. Hoffmann-La Roche

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 3756

    Submission : 1980-02-28

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Harman Finochem

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Harman Finochem

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    USDMF CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2025-10-16

    Valid Till : 2028-07-21

    Written Confirmation Number : WC-0044

    Address of the Firm :

    NDC KDMF VMF Others AUDIT arrow-down
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Granulation

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Topical

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Looking for 50-06-6 / Phenobarbital API manufacturers, exporters & distributors?

    Phenobarbital manufacturers, exporters & distributors 1

    47

    PharmaCompass offers a list of Phenobarbital API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Phenobarbital manufacturer or Phenobarbital supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Phenobarbital manufacturer or Phenobarbital supplier.

    API | Excipient name

    Phenobarbital

    Synonyms

    Phenobarbitone, Luminal, Phenobarbitol, 50-06-6, Phenylethylbarbiturate, Phenobarbituric acid

    Cas Number

    50-06-6

    Unique Ingredient Identifier (UNII)

    YQE403BP4D

    About Phenobarbital

    A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

    Solfoton talpheno Manufacturers

    A Solfoton talpheno manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Solfoton talpheno, including repackagers and relabelers. The FDA regulates Solfoton talpheno manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Solfoton talpheno API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Solfoton talpheno manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

    Solfoton talpheno Suppliers

    A Solfoton talpheno supplier is an individual or a company that provides Solfoton talpheno active pharmaceutical ingredient (API) or Solfoton talpheno finished formulations upon request. The Solfoton talpheno suppliers may include Solfoton talpheno API manufacturers, exporters, distributors and traders.

    click here to find a list of Solfoton talpheno suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

    Solfoton talpheno USDMF

    A Solfoton talpheno DMF (Drug Master File) is a document detailing the whole manufacturing process of Solfoton talpheno active pharmaceutical ingredient (API) in detail. Different forms of Solfoton talpheno DMFs exist exist since differing nations have different regulations, such as Solfoton talpheno USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Solfoton talpheno DMF submitted to regulatory agencies in the US is known as a USDMF. Solfoton talpheno USDMF includes data on Solfoton talpheno's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Solfoton talpheno USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Solfoton talpheno suppliers with USDMF on PharmaCompass.

    Solfoton talpheno JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Solfoton talpheno Drug Master File in Japan (Solfoton talpheno JDMF) empowers Solfoton talpheno API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Solfoton talpheno JDMF during the approval evaluation for pharmaceutical products. At the time of Solfoton talpheno JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Solfoton talpheno suppliers with JDMF on PharmaCompass.

    Solfoton talpheno CEP

    A Solfoton talpheno CEP of the European Pharmacopoeia monograph is often referred to as a Solfoton talpheno Certificate of Suitability (COS). The purpose of a Solfoton talpheno CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Solfoton talpheno EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Solfoton talpheno to their clients by showing that a Solfoton talpheno CEP has been issued for it. The manufacturer submits a Solfoton talpheno CEP (COS) as part of the market authorization procedure, and it takes on the role of a Solfoton talpheno CEP holder for the record. Additionally, the data presented in the Solfoton talpheno CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Solfoton talpheno DMF.

    A Solfoton talpheno CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Solfoton talpheno CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of Solfoton talpheno suppliers with CEP (COS) on PharmaCompass.

    Solfoton talpheno WC

    A Solfoton talpheno written confirmation (Solfoton talpheno WC) is an official document issued by a regulatory agency to a Solfoton talpheno manufacturer, verifying that the manufacturing facility of a Solfoton talpheno active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Solfoton talpheno APIs or Solfoton talpheno finished pharmaceutical products to another nation, regulatory agencies frequently require a Solfoton talpheno WC (written confirmation) as part of the regulatory process.

    click here to find a list of Solfoton talpheno suppliers with Written Confirmation (WC) on PharmaCompass.

    Solfoton talpheno NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Solfoton talpheno as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Solfoton talpheno API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Solfoton talpheno as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Solfoton talpheno and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Solfoton talpheno NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Solfoton talpheno suppliers with NDC on PharmaCompass.

    Solfoton talpheno GMP

    Solfoton talpheno Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Solfoton talpheno GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Solfoton talpheno GMP manufacturer or Solfoton talpheno GMP API supplier for your needs.

    Solfoton talpheno CoA

    A Solfoton talpheno CoA (Certificate of Analysis) is a formal document that attests to Solfoton talpheno's compliance with Solfoton talpheno specifications and serves as a tool for batch-level quality control.

    Solfoton talpheno CoA mostly includes findings from lab analyses of a specific batch. For each Solfoton talpheno CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Solfoton talpheno may be tested according to a variety of international standards, such as European Pharmacopoeia (Solfoton talpheno EP), Solfoton talpheno JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Solfoton talpheno USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search